BIS removes CB proliferation controls for Australia Group destinations and revises Crime Control entries for seven allied countries

Mechanism

The rule makes two distinct regulatory changes under the Export Administration Regulations (EAR):

1. Australia Group CB controls removed for AG-member destinations

The Australia Group is a 43-member multilateral export-control regime whose members maintain harmonised controls on biological and chemical precursors, agents, and equipment that could contribute to CBW programmes. Members include the EU states, US, UK, Australia, Canada, Japan, South Korea, India, Argentina, Mexico, Turkey, and others.

Under this rule, BIS amends the Commerce Country Chart to remove the CB1 (Chemical and Biological Weapons — CB Column 1) reason for control for certain ECCN entries when the export destination is any Australia Group member state. The affected ECCNs include:

• 1C351 — select biological agents (human pathogens, animal

pathogens, plant pathogens, toxins)

• 1C353 — genetic elements and genetically modified organisms
• 1C354 — plant pathogens

The rationale is symmetric reciprocity: AG member states collectively administer equivalent controls on these items. Once CB controls are removed for AG destinations, exporters can ship under No License Required (NLR) rather than applying for a CB-column license, provided no other reason for control applies. Controls for non-AG destinations remain unchanged.

2. Crime Control column revised for seven allied countries

BIS amends the Commerce Country Chart to remove or reduce Crime Control and Detection (CC) column entries for: Austria (AT), Finland (FI), Ireland (IE), Liechtenstein (LI), South Korea (KR), Sweden (SE), and Switzerland (CH).

CC controls apply to law-enforcement equipment that could be used for internal-repression purposes: fingerprint and biometric equipment, lie detectors, certain directed-energy devices, and communications-intercept technology at certain performance thresholds. The revision reflects BIS's updated determination that these seven countries meet the criteria for reduced CC scrutiny — typically membership in the EU, equivalent national legislation, or specific bilateral assurances on end-use.

Regulatory mechanics

Both changes are issued as a direct final rule — BIS invoked the foreign-affairs function exception to APA notice-and-comment, as the changes reduce rather than impose export-license burdens and implement allies' existing control commitments. The rule is effective on publication (December 8, 2023) with no transition period.

The FR document was published at page 85479 of Federal Register Volume 88, Number 235. The BIS contact for the CB portion is Dr. Tara Gonzalez, Chemical and Biological Controls Division, Office of Nonproliferation and Treaty Compliance.

Downstream implications

• Allied biodefense R&D unlocked. Removing CB controls for

AG member destinations eliminates the per-shipment licensing drag on legitimate biodefense, public-health, and academic research collaborations (vaccine development, diagnostic-kit production, select-agent research) among AG-member institutions. The change is particularly relevant to US-EU and US-AU biomedical partnerships where previously a CB license was required even for shipments among parties with identical export-control obligations.

• Law-enforcement tech trade eased for seven allies. The CC

revision for AT, FI, IE, LI, KR, SE, CH reduces friction for US exports of biometric, communications-intercept, and surveillance equipment to those seven governments and their licensed law-enforcement agencies. Beneficiaries include suppliers in the commercial-surveillance and identity- verification technology sectors.

• Regulatory architecture signal. The rule continues the

post-2022 US practice of differentiating allied-country treatment in the EAR architecture — the same directional move seen in the April 2024 AUKUS IFR for Australia and the UK, and in the broader Country Group D:5 rebalancing programme. Taken together, these rules compress the EAR's license-requirement map for close-allied destinations while maintaining or tightening controls for adversary-country routes.

• Severity (2 / qual). The rule is meaningful — it removes

genuine licensing friction for allied markets — but bounded. It does not open new commercial markets, does not involve large dollar volumes, and the items affected (pathogens, toxins, CC equipment) are niche dual-use categories. The equity and trade-flow impact is diffuse and slow to crystallise.

Open questions

• Will BIS extend the CB-column removal to other AG-adjacent

destinations as AG membership expands? (Two applicant states were under consideration as of 2023.)

• The CC revision covers seven specific countries; several

other close allies (e.g. Norway, Iceland) were not included in this batch — watch for a follow-on amendment.

• How does the AG CB-control removal interact with the

October 2023 advanced-biotech export-control rulemaking that BIS was developing in parallel? Any future CB controls on synthetic-biology items could partially re-impose what this rule removes.